Salt inducible kinase inhibitors for enhancing fertility
AssigneeThe Board of Trustees of the University of Illinois
InventorCarlos Stocco
Life of this patent
Estimating the term…
Abstract
This invention relates to methods of using salt inducible kinase inhibitors to enhance female fertility.
Claims32
A method for improving, restoring or enhancing fertility in a female subject comprising administering to the female subject an effective amount of an inhibitor of salt-inducible kinase 2 (SIK2) in combination with an agent of an ovulation induction regimen thereby improving, restoring or enhancing fertility in the female subject, wherein the inhibitor is HG-9-91-01, MRT67307, MRT199665, Dorsomorphin, YKL-06-061, KIN-112, ARN3236, ARN3261, Dasatinib, Bosutinib, or TAE-684.
A method for increasing oocyte production in a female subject comprising administering to the female subject an effective amount of an inhibitor of salt-inducible kinase 2 (SIK2) in combination with an agent of an ovulation induction regimen thereby increasing oocyte production in the female subject, wherein the inhibitor is HG-9-91-01, MRT67307, MRT199665, Dorsomorphin, YKL-06-061, KIN-112, ARN3236, ARN3261, Dasatinib, Bosutinib, or TAE-684.
A method for improving, restoring or enhancing fertility in a female subject comprising administering to the female subject an effective amount of YKL-05-099 in combination with follicle-stimulating hormone thereby improving, restoring or enhancing fertility in the female subject.
A method for increasing oocyte production in a female subject comprising administering to the female subject an effective amount of YKL-05-099 in combination with follicle-stimulating hormone thereby increasing oocyte production in the female subject.
A method for improving, restoring or enhancing fertility in a female subject comprising administering to the female subject an effective amount of an inhibitor of salt-inducible kinase 2 (SIK2) in combination with follicle-stimulating hormone thereby improving, restoring or enhancing fertility in the female subject, wherein the inhibitor is HG-9-91-01, MRT67307, MRT199665, Dorsomorphin, YKL-06-061, KIN-112, ARN3236, ARN3261, Dasatinib, Bosutinib, or TAE-684.
A method for increasing oocyte production in a female subject comprising administering to the female subject an effective amount of an inhibitor of salt-inducible kinase 2 (SIK2) in combination with follicle-stimulating hormone thereby increasing oocyte production in the female subject, wherein the inhibitor is HG-9-91-01, MRT67307, MRT199665, Dorsomorphin, YKL-06-061, KIN-112, ARN3236, ARN3261, Dasatinib, Bosutinib, or TAE-684.
A method for improving, restoring or enhancing fertility in a female subject comprising administering to the female subject an effective amount of YKL-05-099 in combination with an agent of an ovulation induction regimen thereby improving, restoring or enhancing fertility in the female subject.
A method for increasing oocyte production in a female subject comprising administering to the female subject an effective amount of YKL-05-099 in combination with an agent of an ovulation induction regimen thereby increasing oocyte production in the female subject.
Dependencies are inferred from the claim text.